Novel Genetic Signatures Associated With Sporadic Amyotrophic Lateral Sclerosis

Frontiers in Genetics

Robert Logan¹  Sean J. Miller²  Nicolas Schcolnicov²  Juleah Dubel-Haag² 

[1] Department of Biology, Eastern Nazarene College, Quincy, MA, United States;Pluripotent Diagnostics Corp, Colorado Springs, CO, United States;

关键词: amyotrophic lateral sclerosis;    genetics;    dementia;    Ndufs4;    mitochondria;    NADH dehydrogenase;   

DOI  :  10.3389/fgene.2022.851496

来源: DOAJ

【 摘 要 】

Amyotrophic Lateral Sclerosis (ALS) is a complex polygenetic neurodegenerative disorder. Establishing a diagnosis for ALS is a challenging and lengthy process. By the time a diagnosis is made, the lifespan prognosis is only about two to 5 years. Genetic testing can be critical in assessing a patient’s risk for ALS, provided they have one of the known familial genes. However, the vast majority of ALS cases are sporadic and have no known associated genetic signatures. Our analysis of the whole genome sequencing data from ALS patients and healthy controls from the Answer ALS Consortium has uncovered twenty-three novel mutations in twenty-two protein-coding genes associated with sporadic ALS cases. The results show the majority of patients with the sporadic form of ALS have at least one or more mutation(s) in the 22 genes we have identified with probabilities of developing ALS ranging from 25–99%, depending on the number of mutations a patient has among the identified genes. Moreover, we have identified a subset of the ALS cohort that has >17 mutations in the 22 identified. In this case, a patient with this mutation profile has a 99% chance of developing ALS and could be classified as being at high risk for the disease. These genetic biomarkers can be used as an early ALS disease diagnostic tool with a rapid and non-invasive technique.

【 授权许可】

Unknown